Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors

Molecular Pharmacology

Volumn 80, Issue 3, 2011, Pages 538-549

  Hanna, Amy D ^a   Janczura, Marie ^a   Cho, Eric ^a   Dulhunty, Angela F ^a   Beard, Nicole A ^a  

^a Biology and Environment   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALSEQUESTRIN; DAUNORUBICIN; DITHIOTHREITOL; RYANODINE RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SHEEP;

ANIMALS; ANTINEOPLASTIC AGENTS; DAUNORUBICIN; HEART; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SHEEP;

EID: 80051982074     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.073478     Document Type: Article

References (49)

1. Abbott RE and Schachter D. (1976) Impermeant maleimides. Oriented probes of erythrocyte membrane proteins. J Biol Chem 251:7176-7183.
2. Abramson J.J., Buck E., Salama G., Casida JE, and Pessah I.N. (1988) Mechanism of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum. J Biol Chem 263:18750-18758. (Pubitemid 19016332)
3. Arai M., Tomaru K., Takizawa T., Sekiguchi K., Yokoyama T., Suzuki T, and Nagai R. (1998) Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol 30:243-254. (Pubitemid 28116304)
4. Beard N.A., Casarotto M.G., Wei L., Varsányi M., Laver DR, and Dulhunty A.F. (2005) Regulation of ryanodine receptors by calsequestrin: Effect of high luminal Ca2+and phosphorylation. Biophys J 88:3444-3454. (Pubitemid 40586594)
5. Beard N.A., Sakowska M.M., Dulhunty AF, and Laver D.R. (2002) Calsequestrin is an inhibitor of skeletal muscle ryanodine receptor calcium release channels. Biophys J 82:310-320. (Pubitemid 34289804)
6. 2+ binding capacity and promotes its association with junctin. Cell Calcium 44:363-373.
7. Bers D.M. (2002) Calcium and cardiac rhythms: Physiological and pathophysiological. Circ Res 90:14-17.
8. Brini M. (2004) Ryanodine receptor defects in muscle genetic diseases. Biochem Biophys Res Commun 322:1245-1255.
9. Charlier H.A. Jr, Olson R.D., Thornock C.M., Mercer W.K., Olson D.R., Broyles T.S., Muhlestein D.J., Larson C.L., Cusack BJ, and Shadle S.E. (2005) Investigations of calsequestrin as a target for anthracyclines: Comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. Mol Pharmacol 67:1505-1512. (Pubitemid 40594149)
10. Cleland W.W. (1964) Dithiothreitol, a new protective reagent for Sh groups. Biochemistry 3:480-482.
11. 2+ gating of skeletal muscle and cardiac ryanodine receptors. Biophys J 73:141-156.
12. Dulhunty A.F., Laver D.R., Gallant E.M., Casarotto M.G., Pace SM, and Curtis S. (1999) Activation and inhibition of skeletal RyR channels by a part of the skeletal DHPR II-III loop: Effects of DHPR Ser687 and FKBP12. Biophys J 77:189-203. (Pubitemid 29305220)
13. Dulhunty A.F., Pouliquin P., Coggan M., Gage PW, and Board P.G. (2005) A recently identified member of the glutathione transferase structural family modifies cardiac RyR2 substate activity, coupled gating and activation by Ca2+ and ATP. Biochem J 390:333-343. (Pubitemid 41192260)
14. Eager KR and Dulhunty A.F. (1999) Cardiac ryanodine receptor activity is altered by oxidizing reagents in either the luminal or cytoplasmic solution. J Membr Biol 167:205-214. (Pubitemid 29081356)
15. 2+-release channels from sheep myocardium. Am J Physiol 272:C1908-C1918.
16. Feng W., Liu G., Xia R., Abramson JJ, and Pessah I.N. (1999) Site-selective modification of hyperreactive cysteines of ryanodine receptor complex by quinones. Mol Pharmacol 55:821-831. (Pubitemid 29214601)
17. Gambliel H.A., Burke B.E., Cusack B.J., Walsh G.M., Zhang Y.L., Mushlin PS, and Olson R.D. (2002) Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem Biophys Res Commun 291:433-438. (Pubitemid 34687364)
18. Gomez AM and Richard S. (2004) Mutant cardiac ryanodine receptors and ventricular arrhythmias: Is 'gain-of-function' obligatory? Cardiovasc Res 64:3-5. (Pubitemid 39208916)
19. Györke S and Terentyev D. (2008) Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. Cardiovasc Res 77:245-255. (Pubitemid 351197640)
20. Hidalgo C and Donoso P. (2008) Crosstalk between calcium and redox signaling: From molecular mechanisms to health implications. Antioxid Redox Signal 10:1275-1312. (Pubitemid 351634396)
21. Holmberg SR and Williams A.J. (1990) Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. Circ Res 67:272-283. (Pubitemid 20242568)
22. Jalilian C., Gallant E.M., Board PG, and Dulhunty A.F. (2008) Redox potential and the response of cardiac ryanodine receptors to CLIC-2, a member of the glutathione S-transferase structural family. Antioxid Redox Signal 10:1675-1686.
23. Jessup M and Brozena S. (2003) Heart failure. N Engl J Med 348:2007-2018.
24. Kim E., Tam M., Siems WF, and Kang C. (2005) Effects of drugs with muscle-related side effects and affinity for calsequestrin on the calcium regulatory function of sarcoplasmic reticulum microsomes. Mol Pharmacol 68:1708-1715. (Pubitemid 41654354)
25. Kim E., Youn B., Kemper L., Campbell C., Milting H., Varsanyi M, and Kang C. (2007) Characterization of human cardiac calsequestrin and its deleterious mutants. J Mol Biol 373:1047-1057. (Pubitemid 47498443)
26. Kumar D., Kirshenbaum L.A., Li T., Danelisen I, and Singal P.K. (2001) Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 3:135-145. (Pubitemid 32240636)
27. Lahat H., Pras E., Olender T., Avidan N., Ben-Asher E., Man O., Levy-Nissenbaum E., Khoury A., Lorber A., Goldman B., et al. (2001) A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69:1378-1384. (Pubitemid 33124218)
28. 2+ inhibits the ryanodine receptor from cardiac muscle. J Membr Biol 147:7-22.
29. Marengo J.J., Hidalgo C, and Bull R. (1998) Sulfhydryl oxidation modifies the calcium dependence of ryanodine-sensitive calcium channels of excitable cells. Biophys J 74:1263-1277. (Pubitemid 28108536)
30. Marinov B.S., Olojo R.O., Xia R, and Abramson J.J. (2007) Non-thiol reagents regulate ryanodine receptor function by redox interactions that modify reactive thiols. Antioxid Redox Signal 9:609-621. (Pubitemid 46598259)
31. Maruyama K., Mikawa T, and Ebashi S. (1984) Detection of calcium binding proteins by 45Ca autoradiography on nitrocellulose membrane after sodium dodecyl sulfate gel electrophoresis. J Biochem 95:511-519.
32. Menna P., Minotti G, and Salvatorelli E. (2007) In vitro modeling of the structureactivity determinants of anthracycline cardiotoxicity. Cell Biol Toxicol 23:49-62. (Pubitemid 44950188)
33. Mertens A.C., Yasui Y., Neglia J.P., Potter J.D., Nesbit M.E. Jr, Ruccione K., Smithson WA, and Robison L.L. (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 19:3163-3172. (Pubitemid 32591432)
34. Minotti G., Menna P., Salvatorelli E., Cairo G, and Gianni L. (2004) Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229. (Pubitemid 38720829)
35. 2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 117:2431-2444.
36. Olson R.D., Li X., Palade P., Shadle S.E., Mushlin P.S., Gambliel H.A., Fill M., Boucek R.J. Jr, and Cusack B.J. (2000) Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol Appl Pharmacol 169:168-176.
37. Ondrias K., Borgatta L., Kim DH, and Ehrlich B.E. (1990) Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. Circ Res 67:1167-1174. (Pubitemid 20368014)
38. Park I.Y., Kim E.J., Park H., Fields K., Dunker AK, and Kang C. (2005) Interaction between cardiac calsequestrin and drugs with known cardiotoxicity. Mol Pharmacol 67:97-104. (Pubitemid 40073631)
39. 2+ release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol 37:503-514.
40. Pessah I.N., Kim KH, and Feng W. (2002) Redox sensing properties of the ryanodine receptor complex. Front Biosci 7:a72-79.
41. Rang H.P. (2007) Rang and Dale's Pharmacology, Elsevier, Philadelphia.
42. 2+ transport ATPase by thapsigargin at subnanomolar concentrations. J Biol Chem 266:13503-13506.
43. Shadle S.E., Bammel B.P., Cusack B.J., Knighton R.A., Olson S.J., Mushlin PS, and Olson R.D. (2000) Daunorubicin cardiotoxicity: Evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol 60:1435-1444.
44. Shan K., Lincoff AM, and Young J.B. (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58.
45. 2+ leak in chronic heart failure. Circ Res 103:1466-1472.
46. Wei L., Hanna A.D., Beard NA, and Dulhunty A.F. (2009) Unique isoform-specific properties of calsequestrin in the heart and skeletal muscle. Cell Calcium 45:474-484.
47. White M. (1999) Principles of pharmacokinetics, in Clinical Pharmacology for Anaesthetists (Bovill JG and Howie MB eds) pp 21-34, Harcourt Publishers, London.
48. Zhang N, Schuchmann HP, and Sonntag CV (1991) The reaction of superoxide radical anion with dithiothreitol: A chain process. J Phys Chem 95:4718-4722.
49. 2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev 49:1-51.